Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
Roche secures a front-line liver cancer label, but rival data at Asco show that the competition isn’t resting on its laurels.
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
Daridorexant scores in the first of two phase III insomnia studies, but attention will fall on a secondary endpoint measuring daytime performance.
Genmab is seeking data to position tisotumab as its first in-house launch, while Zogenix wants Fintepla to challenge GW in Lennox-Gastaut syndrome.
Biogen’s Alzheimer’s candidate and Fibrogen’s new anaemia pill top the list of the biggest commercial hopes that could reach the market in 2020.
The first-line Checkmate-9ER study will read out soon, and could show whether two arch rivals can together defeat a common enemy.
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
The amyloid-beta project is to be filed for Alzheimer’s, and Biogen’s market cap regains the $15bn it lost in March.